Pfizer Inc PFE
We take great care to ensure that the data presented and summarized in this overview for PFIZER INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PFE
View all-
Vanguard Group Inc Valley Forge, PA519MShares$13.7 Billion0.25% of portfolio
-
Black Rock Inc. New York, NY424MShares$11.2 Billion0.27% of portfolio
-
State Street Corp Boston, MA290MShares$7.68 Billion0.31% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA155MShares$4.11 Billion0.78% of portfolio
-
Wellington Management Group LLP Boston, MA140MShares$3.7 Billion0.7% of portfolio
-
Geode Capital Management, LLC Boston, MA121MShares$3.19 Billion0.25% of portfolio
-
Norges Bank Oslo, Q887.8MShares$2.32 Billion0.32% of portfolio
-
Massachusetts Financial Services CO Boston, MA76.5MShares$2.02 Billion0.68% of portfolio
-
Morgan Stanley New York, NY73.9MShares$1.95 Billion0.14% of portfolio
-
Northern Trust Corp Chicago, IL58.4MShares$1.54 Billion0.22% of portfolio
Latest Institutional Activity in PFE
Top Purchases
Top Sells
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Transactions at PFE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 26
2025
|
Michael Mc Dermott Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,220
-4.17%
|
$83,720
$26.42 P/Share
|
Feb 26
2025
|
Christoffel Boshoff President, R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
4,872
-3.05%
|
$126,672
$26.42 P/Share
|
Feb 26
2025
|
Christoffel Boshoff President, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
9,687
+5.71%
|
-
|
Feb 23
2025
|
Jennifer B. Damico SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
390
-4.14%
|
$10,140
$26.3 P/Share
|
Feb 23
2025
|
Christoffel Boshoff President, R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
662
-0.44%
|
$17,212
$26.3 P/Share
|
Feb 22
2025
|
Jennifer B. Damico SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
8,188
-23.76%
|
$212,888
$26.19 P/Share
|
Feb 22
2025
|
Jennifer B. Damico SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
8,741
+33.18%
|
$262,230
$30.17 P/Share
|
Feb 22
2025
|
Michael Mc Dermott Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
10,422
-5.98%
|
$270,972
$26.19 P/Share
|
Feb 22
2025
|
Michael Mc Dermott Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
11,125
+11.26%
|
$333,750
$30.17 P/Share
|
Feb 22
2025
|
Douglas M Lankler Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
79,899
-17.4%
|
$2,077,374
$26.19 P/Share
|
Feb 22
2025
|
Douglas M Lankler Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
85,824
+26.94%
|
$2,574,720
$30.17 P/Share
|
Feb 22
2025
|
Albert Bourla Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
221,515
-19.71%
|
$5,759,390
$26.19 P/Share
|
Feb 22
2025
|
Albert Bourla Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
238,399
+29.47%
|
$7,151,970
$30.17 P/Share
|
Feb 22
2025
|
Sally Susman Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
59,500
-13.37%
|
$1,547,000
$26.19 P/Share
|
Feb 22
2025
|
Sally Susman Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
63,573
+22.02%
|
$1,907,190
$30.17 P/Share
|
Feb 22
2025
|
Payal Sahni Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
11,911
-16.29%
|
$309,686
$26.19 P/Share
|
Feb 22
2025
|
Payal Sahni Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
12,714
+25.52%
|
$381,420
$30.17 P/Share
|
Feb 22
2025
|
Christoffel Boshoff President, R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
8,138
-2.56%
|
$211,588
$26.19 P/Share
|
Feb 22
2025
|
Christoffel Boshoff President, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,741
+5.21%
|
$262,230
$30.17 P/Share
|
Feb 13
2025
|
Ronald E Blaylock Director |
BUY
Open market or private purchase
|
Direct |
19,457
+41.25%
|
$486,425
$25.65 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 429K shares |
---|---|
Open market or private purchase | 20.5K shares |
Grant, award, or other acquisition | 9.69K shares |
Payment of exercise price or tax liability | 453K shares |
---|---|
Open market or private sale | 5.15K shares |